March 4, 2024

FDA Accepts Molecular Templates IND for MT-8421 ETB Program Targeting CTLA-4

(24/7 MARKET NEWS) – Molecular Templates, Inc. (NASDAQ:MTEM) announced, during yesterday’s market hours, that it received FDA clearance following review of its Investigational New Drug Application (“IND”) to proceed for clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.

Molecular Templates is trading at $0.60 up $0.13 (+27.23%), on 6.8 million premarket shares.

Its 52-week trading range is $0.31 to $3.6365. It’s trading at new 2023 highs and above yesterday’s $0.55 high, on much higher volume, so this is a move to keep an eye on, as there are only low volume resistance points to July’s $1 trading level.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.